Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | PTX-912 |
| Synonyms | |
| Therapy Description |
PTX-912 is a fusion protein comprising an anti-PDCD1 (PD1) monoclonal antibody linked to a conditionally masked IL-2, which potentially enhances antitumor immune response and inhibits tumor growth (Journal for ImmunoTherapy of Cancer 2024;12). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| PTX-912 | PTX 912|PTX912 | PD-L1/PD-1 antibody 133 | PTX-912 is a fusion protein comprising an anti-PDCD1 (PD1) monoclonal antibody linked to a conditionally masked IL-2, which potentially enhances antitumor immune response and inhibits tumor growth (Journal for ImmunoTherapy of Cancer 2024;12). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06190886 | Phase I | PTX-912 | A First-in-human (FIH), Phase I Study of PTX-912 in Patients with Locally Advanced/Metastatic Solid Tumors | Recruiting | USA | 0 |